Paul Audhya compensation by year
KalVista Pharmaceuticals Summary Compensation Table · the one fiscal year held| Component | FY2024 |
|---|---|
| Salary | $502,900 |
| Bonus | $221,276 |
| Stock awards | $1,097,159 |
| Option awards | $0 |
| Non-equity incentive | $0 |
| Pension and deferred compensation | $0 |
| All other | $12,639 |
| Total | $1,833,974 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: KalVista Pharmaceuticals, Inc. DEF 14A filed August 21, 2025, accession 0001193125-25-185353, and prior-year filings. Open the filing on EDGAR.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 100,000 | $1,003,000 | — |
| RSU | 65,000 | $759,850 | — |
| RSU | 12,094 | $112,232 | — |
| RSU | 12,084 | $82,413 | — |
| Option | 6,988 | — | $9.28 |
| Option | 2,084 | — | $24.97 |
Per the Outstanding Equity Awards at Fiscal Year-End table in KalVista Pharmaceuticals, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
42 Form 4 lines since the FY2024 proxy (filed August 21, 2025)current to 2026-09-24 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-06-11 | Disposition to the issuer derivative | — | 40,000 | — | 0 |
| 2026-06-11 | Disposition to the issuer derivative | — | 93,750 | — | 0 |
| 2026-06-11 | Disposition to the issuer | — | 150,260 | $0.00 | 0 |
| 2026-06-11 | Disposition to the issuer derivative | — | 100,000 | — | 0 |
| 2026-06-11 | Disposition to the issuer derivative | — | 68,750 | — | 0 |
| 2026-06-11 | Disposition to the issuer derivative | — | 25,800 | — | 0 |
| 2026-05-26 | Sale | — | 2,239 | $26.78 | 150,260 |
| 2026-05-22 | Sale | — | 2,685 | $26.78 | 147,499 |
The 8 most recent of 42 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
KalVista Pharmaceuticals’s named executive officers, FY2024
as the company reported each| Named executive officer | Role | FY2024 total |
|---|---|---|
| Benjamin Palleiko | Chief Executive Officer | $6,772,197 |
| Brian Piekos | Chief Financial Officer | $2,144,133 |
| Paul Audhya · this page | Chief Medical Officer | $1,833,974 |
The full KalVista Pharmaceuticals compensation record
free company briefThis page is one person within KalVista Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order KalVista Pharmaceuticals's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are KalVista Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Velarion Pro: every company page, peer tools and exports, one seat